Statins for Hyperlipidemia in Patients With Chronic Liver Disease: Are They Safe?

Clinical Gastroenterology and Hepatology

Volumn 4, Issue 7, 2006, Pages 838-839

  Vuppalanchi, Raj ^a   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ATORVASTATIN; DICLOFENAC; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; PREDNISONE; TETRAHYDROLIPSTATIN;

AUTOIMMUNE HEPATITIS; CHOLESTATIC HEPATITIS; CHRONIC DISEASE; CLINICAL FEATURE; DRUG MONITORING; EDITORIAL; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; PATIENT ASSESSMENT; PATIENT MONITORING; PRESCRIPTION;

CHRONIC DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIVER DISEASES;

EID: 33745633056     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.04.020     Document Type: Editorial

References (16)

1. Available at: http://www.drugtopics.com/drugtopics. Accessed: April 6, 2006.
2. Pasternal R.C., Smith S.C., Bairez-Merz C., et al. ACC/AHA/NIHLBI clinical advisory on the use and safety of statins. Circulation 106 (2002) 1024-1028
3. Chalasani N. Statin hepatotoxicity. focus on statin usage in nonalcoholic fatty liver disease. Hepatology 41 (2005) 690-695
4. The Physician Desk Reference. 59th ed. (2005), Thompson HealthCare, Montvale, NJ
5. Chalasani N., Aljadhey H., Kesterson J., et al. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 128 (2004) 1287-1292
6. Vuppalanchi R., Teal E., and Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 329 (2005) 62-65
7. Khorashadi S., Hasson N.K., and Cheung R.C. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 4 (2006) 902-907
8. Cohen D., Anania F., Chalasani N., Statin Safety Task Force, and National Lipid Association. Report of the liver expert panel. Am J Cardiol 97 Suppl (2006) 77C-81C
9. Avins A.L., Manos M.M., Levin T.R., et al. Lovastatin is not hepatotoxic to patients with pre-existing liver disease. (abstr). Gastroenterology 130 (2006) A595
10. Senior J.R. Regulatory perspective. In: Kaplowitz N., and DeLeve L.D. (Eds). Drug induced liver disease (2003), Marcel Dekker, Inc, New York 739-754
11. Stolk M.F.J., Becx M.C.J.M., Kuypers K.C., et al. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol 4 (2006) 908-911
12. van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem 42 (2005) 402-404
13. Andrade R., Lucena M., Vega J., et al. Acarbose-associated hepatotoxicity. Diabetes Care 21 (1998) 2029-2030
14. Fujimoto Y., Ohhira M., Miyokawa N., et al. Acarbose-induced hepatic injury. Lancet 351 (1998) 340
15. Kim D.H., Lee E.H., Hwang J.C., et al. A case of acute cholestatic hepatitis associated with Orlistat. Taehan Kan Hakhoe Chi 8 (2002) 317-320
16. Lau G., and Chan C.L. Massive hepatocellular [correction of hepatocullular] necrosis. was it caused by Orlistat?. Med Sci Law 42 (2002) 309-312